**Table 1:** **Final Items for the Treatment Satisfaction Questionnaire for Medication (TSQM)** **[19]**

1 How satisfied or dissatisfied are you with the ability of the medication to prevent or treat your condition?

2 How satisfied or dissatisfied are you with the way the medication relieves your symptoms?

3 How satisfied or dissatisfied are you with the amount of time it takes the medication to start working?

4 As a result of taking this medication, do you currently experience any side effects at all?

5 How bothersome are the side effects of the medication you take to treat your condition?

6 To what extent do the side effects interfere with your physical health and ability to function (i.e., strength, energy levels, etc.)?

7 To what extent do the side effects interfere with your mental function (i.e., ability to think clearly, stay awake, etc.)?

8 To what degree have medication side effects affected your overall satisfaction with the medication?

9 How easy or difficult is it to use the medication in its current form?

10 How easy or difficult is it to plan when you will use the medication each time?

11 How convenient or inconvenient is it to take the medication as instructed?

12 Overall, how confident are you that taking this medication is a good thing for you?

13 How certain are you that the good things about your medication outweigh the bad things?

14 Taking all things into account, how satisfied or dissatisfied are you with this medication?

**TABLE 2 pre-operative characteristics of the patients**

|  |  |
| --- | --- |
| **Variable** | **Patients (n 50)** |
| Median age (yrs) | 64.1  (IQR 46-79) |
| Median ASA score | 2  (IQR 1-3) |
| Median PSA (ng/ml)  Prior prostate biopsy | 3.79  (IQR 0.41-23)  4 (8%) |
| Median prostate size (ml)  Middle lobe rate (n, %) | 68.6  (IQR 40-160)  35 (70%) |
| AB therapy (n) | 50 |
| 5ARI therapy (n) | 5 |
| Preoperative median IPSS | 27.1  (IQR 14-35) |
| Preoperative median Qmax (ml/s) | 10.1  (IQR 3.5–16.4) |
| Preoperative median postvoid residual (ml) | 101.3  (IQR 33–250) |

**TABLE 3 Postoperative outcomes**

|  |  |
| --- | --- |
| **Variable** | **Patients (n 50)** |
| Median operative time (minutes) | 11.44  (IQR 7–16) |
| median PEEK vapor needle injection | 7.2  (IQR 4–14) |
| the median time for dismissal after the procedure (hour) | 1.5  (IQR 1-2) |
| Median indwelling urinary catheter time (days) | 11.7  (IQR 10–30) |
| Postoperative median IPSS  1 month  3 month  6 month | 616.8 (IQR 7–32)  9.6 (IQR 2–22)  5.3 (IQR 0–12) |
| VAS  1st postoperative day  10th postoperative day  30th postoperative day | 2.9 (IQR 2-4)  1.6 (IQR 1-3)  0.06 (IQR 0-1) |
| TSQM  Effectiveness  side effect  convenience  satisfaction | 75.2 (IQR 50-100)  100.0 (IQR 100-100)  82.5 (IQR50-100)  85.9 (IQR50-100) |